Tafolecimab Biosimilar (PCSK9 Reference Antibody)
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia.
Product Specifications
Target
Tafolecimab Biosimilar (Anti-PCSK9 Reference Antibody)
Clonality
Monoclonal
Conjugation
Unconjugated
Field of Research
Metabolism Research
Purity
>98%
Storage Conditions
Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Notes
For research use only.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
262700-01 5 mg
5,7-Bis- (benzyloxy) -2- (4- (benzyloxy) phenyl) -4H-chromen-4-one
Sign In for Pricing
View Details 262700-02 10 mg
5,7-Bis- (benzyloxy) -2- (4- (benzyloxy) phenyl) -4H-chromen-4-one
Sign In for Pricing
View Details 262700-03 25 mg
5,7-Bis- (benzyloxy) -2- (4- (benzyloxy) phenyl) -4H-chromen-4-one
Sign In for Pricing
View Details 262700-04 50 mg
5,7-Bis- (benzyloxy) -2- (4- (benzyloxy) phenyl) -4H-chromen-4-one
Sign In for Pricing
View Details 262700-05 100 mg
5,7-Bis- (benzyloxy) -2- (4- (benzyloxy) phenyl) -4H-chromen-4-one
Sign In for Pricing
View Details 